Results: 3

1.
Fig. 2.

Fig. 2. From: Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C.

Maximum steady-state plasma concentrations for silymarin flavonolignans at 560 mg of silymarin in HCV (■) and NAFLD (□) subjects. Plasma concentrations of isosilybin A, isosilybin B, silychristin, and silydianin were significantly greater in NAFLD subjects compared with HCV subjects. Silychristin and silydianin were not detected in the plasma of HCV subjects.

Sarah J. Schrieber, et al. Drug Metab Dispos. 2011 December;39(12):2182-2190.
2.
Fig. 1.

Fig. 1. From: Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C.

Steady-state plasma concentration versus time profiles for silybin B conjugates and parent silybin B (inset) at 280 mg of silymarin in HCV (●) and NAFLD (□) subjects. Forty-eight-hour plasma samples were obtained after a final single-dose administration after an every 8 h for 7-day dose regimen. AUC0–8 h and Cmax for silybin B conjugates were 46 and 42% lower, respectively, in NAFLD subjects compared with HCV; p < 0.05.

Sarah J. Schrieber, et al. Drug Metab Dispos. 2011 December;39(12):2182-2190.
3.
Fig. 3.

Fig. 3. From: Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C.

Steady-state plasma concentration versus time profiles for silymarin flavonolignans at 560 mg of silymarin in HCV and NAFLD subjects. Forty-eight-hour plasma samples were obtained after a final single dose administration after an every 8 h for 7-day dose regimen. Evidence of enterohepatic recycling of flavonolignans by the appearance of secondary peaks was observed in NAFLD subjects (——), whereas no evidence of enterohepatic recycling for silybin A or silybin B was observed in HCV subjects (– – –). In addition to silybin A and silybin B, silychristin (▴) represented a major flavonolignan in NAFLD subjects. For presentation clarity, error bars were not included.

Sarah J. Schrieber, et al. Drug Metab Dispos. 2011 December;39(12):2182-2190.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk